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Head and neck cancer
Radiation
Chk1 inhibitionPurpose: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several
tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have
been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities.
Materials and methods: We characterized the radiosensitizing activity of CCT244747, the first orally
bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and moni-
tored the effect of combining CCT244747 with radiation both in in vitro and in vivo models.
Results: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in can-
cer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of
the radiation-induced G2 arrest and premature entry into mitosis.
Conclusions: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It
radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination
with radiotherapy.
 2017 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 122 (2017) 470–475
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Despite significant advances in treatments for locally-advanced
bladder and head and neck squamous cell cancers (HNSCC), the 5-
year disease-specific survival rates are poor [1,2]. Most patients
receive radiotherapy (RT), either as primary RT/chemoradiother-
apy (CRT) in an organ-sparing approach, or post-operatively, as
adjuvant RT/CRT. Unfortunately, failure to achieve loco-regional
disease control and significant radiation-induced treatment toxic-
ities mean that outcomes are suboptimal in many patients.
One strategy to improve the efficacy of RT is to target signalling
pathways activated by radiation. Chk1 is one of the main regula-
tors of the G2/M checkpoint and an essential signal transducer in
the cellular response to DNA damage and replication stress [3,4].
Therefore, this kinase represents an attractive target for sensitizing
cancer cells to both RT and chemotherapy. Previous studies have
shown that selectively targeting the G2/M cell cycle checkpoint
can improve cancer cell sensitivity to RT [5,6]. A number of Chk1
inhibitors have demonstrated tumour-specific radiosensitization
in preclinical studies [7–9]. However, their translation into clinicaltrials has been limited by difficulties with pharmaceutical formula-
tion and toxicity. Here, we present data on CCT244747, a potent,
non-toxic, orally bioavailable Chk1 inhibitor [10] that mediates
in vitro and in vivo radiosensitization by modulating G2/M check-
point control. We show that death occurs through mitotic catastro-
phe and/or apoptosis in cells cycling with unrepaired DNA damage.Materials and methods
Cell lines, drug treatment and irradiation
RT112, T24 (bladder) and Cal27 (HNSCC) were obtained from
ATCC. hTertRPE1 epithelial cells were obtained from Dr. C. Bakal
(ICR), London. All cancer cell lines were typed using short tandem
repeat analysis (Bio-Synthesis Inc., Texas, USA). Cells were cultured
in 10% Foetal Bovine serum (FBS) (Gibco by life technologies), 1%
glutamine and 0.5% penicillin/streptomycin, in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (ICR, London, UK) and routinely
tested for mycoplasma. CCT244747 was synthesized by the ICR,
Sutton and dissolved in dimethyl sulfoxide (DMSO) (Fisher Scien-
tific) for in vitro experiments and in 10% DMSO, 5% Tween-80,
20% PEG400 (Sigma–Aldrich) and 65% H2O for in vivo experiments.
Irradiation was carried out as previously described [7].
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Cells were seeded into 6-well plates and, 16–24 h later, treated
with CCT244747 (0.25 lM, 0.5 lM or 2 lM). Plates were irradiated
(2, 4 or 6 Gy) 6 h post-treatment with CCT244727. Medium was
replaced 48 h after treatment with CCT244747. Cells were fixed
and stained using 5% glutaraldehyde and 0.05% crystal violet
(Sigma–Aldrich) 10–20 days after treatment. Colonies (P50 cells)
were counted manually. Surviving fractions were calculated as a
ratio of the untreated control cells after normalizing for plating
efficiency. Survival curves were generated using Prism 6, (Graph-
Pad Software, San Diego, California, USA). Statistical differences
were analysed with a 2-way ANOVA test.Cell cycle distribution
Cells were seeded in 10 cm dishes and, 48 h later, treated with
4 lM CCT244747. Plates were irradiated with 8 Gy in a single frac-
tion 6 h after exposure to CCT244747. Cells were fixed with 70%
ethanol at indicated time points with CCT244747 and stained with
pS10 histone H3 conjugated Alexa (R)647 antibody (Cell Signalling)
and propidium iodide. Flow cytometry analysis was performed
using a LSRII flow cytometer (BD Biosciences, Oxford, UK).Western blotting analysis
Cells were seeded and treated with CCT244747 and radiation as
described above. Whole-cell lysates were collected using radioim-
munoprecipitation assay (RIPA) buffer at selected time-points after
treatment with CCT244747. The following antibodies were used for
western blotting: pS345 Chk1, total Chk1, Caspase-3, pS139 His-
tone H2A.X, b-Actin and GAPDH (Cell Signalling), PARP-1 (Santa
Cruz Biotechnology) and pS10 Histone H3 (Merck Millipore).Immunofluorescence analysis
Cells were plated in 35 mm glass-bottomed, collagen-coated
dishes (MatTek, Massachusetts, USA) and irradiated with 4 Gy 6 h
after treatment with 4 lM CCT244747. Cells were fixed with 4%
formaldehyde at the indicated time points and immunofluores-
cence was performed as previously described [7]. Cells were
stained with pS139 Histone H2A.X (c-H2AX; Cell signalling) and
a-Tubulin (Sigma Aldrich) and visualized using Alexafluor-488-
conjugated goat anti-rabbit and Alexfluor-546-conjugated goat
anti-mouse antibodies (InvitrogenTM, Life technologies) along with
40,6-diamidino-2-phenylindole, dihydrochloride (DAPI; Invitrogen,
Molecular ProbesTM) nuclear stain. A minimum of 100 nuclei were
examined. Nuclei were quantified as positive for foci whenP5 foci
were present within the nucleus, positive for pan-nuclear staining
when P80% of the nucleus was stained positive for c-H2AX.
Micronucleated or multinucleated cells were scored as abnormal.In vivo studies
Female 5- to 6-week-old athymic nude mice (CD-1 Nude
Mouse Crl:CD1-Foxn1nu, Charles River) were used. All experiments
were approved by the institutional review board in compliance
with NCRI guidelines. 3  106 Cal27 cells were injected subcuta-
neously in the right flank. Once tumours had reached approxi-
mately 5 mm diameter, animals were randomized into 4 groups
(n = 8): control, RT, single-agent CCT244747 and CCT244747 plus
RT. Radiotherapy consisted of a total dose of 10 Gy in 5 fractions
on alternate days. CCT244747 (100 mg/kg) was administered by
gavage 1 h before each radiation fraction [10]. Tumour volume
was calculated as Volume = (Width2  Length)/2). Body weights
were taken twice weekly. The time taken to reach the experimentalendpoint (tumour diameter > 15 mm) in each group was compared
by log-rank test.Results
CCT244747 radiosensitizes bladder and head and neck cancer cell lines
There was a significant difference between 0 and 2 Gy radiation
when T24, RT112 and Cal27 cancer cells were treated with 0.5 lM
CCT244747. This effect was not evident in hTertRPE1 epithelial
cells (Fig 1a). The dose modifying factor (DMF) was calculated to
quantify the degree of sensitization (Fig. S1a and b). This showed
a marked dose-modifying effect in T24, RT112 and Cal27 cancer
cells that was not seen in hTertRPE1 epithelial cells, indicating can-
cer cell-specific radiosensitization by CCT244747.
The on-target effect of CCT244747 was evaluated using western
blot analysis at 8 and 12 h after treatment with 4 lM CCT244747.
CCT244747 induced phosphorylation at the Ser345 (pS345) site on
Chk1, indicating increased DNA damage and protein phosphatase
PP2A inhibition [11]. Radiation-induced pS345-Chk1 was evident
in T24 and RT112 cell lines, but not to the same extent as for
single-agent CCT244747 treatment. Combining CCT244747 with
radiation increased pS345-Chk1 above levels seen with
CCT244747 alone in T24, RT112 and Cal27 (Fig. 1c).CCT244747 abrogates RT-induced G2 arrest
To determine whether CCT244747 would modify radiation-
mediated cell cycle changes, cells were treated with CCT244747
6 h before irradiation. To calculate the percentage of cells in mito-
sis, cells were stained for pS10-Histone H3 (p-HH3) and analysed
by flow cytometry. Treatment with CCT244747 significantly abro-
gated radiation-mediated G2 arrest at 12 h (Fig. 2a). This continued
cell cycling following irradiation, due to the presence of
CCT244747, led to a significant increase in the mitotic and G1 pop-
ulations in RT112 and Cal27 cells at 12 h and the S phase popula-
tion in all cells lines at 24 h (Fig. S2).
All cell lines exhibited a significant increase in the G2 phase of
the cell cycle and a decrease in the mitotic population at 6 h post-
irradiation (12 h time point), indicating a DNA damage-induced G2
arrest (Fig 2a). Irradiation of cells with 8 Gy caused a decrease in
the G1 population and a small increase in the S phase population
at 12 h after treatment. Both G1 and S phase populations were
decreased in all cell lines at 24 h post-irradiation (Fig. S2).
CCT244747 alone reduced the G2 population in T24 and Cal27
cells and the mitotic population in T24 cells at 12 h. This effect
was not seen in RT112 cells and had recovered in other cells by
24 h (Fig. 2a). There was also an observable increase in the S phase
population in all cells 12 and 24 h post-treatment with CCT244747
(Fig. S2). This increase in the S phase may represent Chk1-
dependent stalled replication [3,12].
The flow cytometry results were confirmed by Western blotting
for p-HH3, where a decrease in the expression of p-HH3 indicated
G2 arrest. A dramatic reduction in the expression of p-HH3 was
seen 6 h after irradiation in all cell lines (12 h time point) (Fig 2b).
Treatment with CCT244747 abrogated radiation-mediated G2
arrest resulting in an increase in the expression of p-HH3 at 12–
48 h after treatment (compared to radiation alone).
To examine whether cells were dying by apoptosis or becoming
aneuploid 48 h after treatment, the sub-G1 and aneuploid (>4 N)
populations were analysed by flow cytometry. Following
CCT244747 and RT double therapy, there was a significant increase
in the sub-G1 population in T24 and RT112 cells (Fig 2a). Although
aneuploidy was increased following RT, addition of CCT244747 did
not further increase the percentage of aneuploid cells present 48 h
after therapy (Fig 2a).
Fig. 1. CCT244747 increases the sensitivity of T24, RT112 and Cal27 cancer cell lines to radiation. (a) Clonogenic survival of T24, RT112 and Cal27 cancer cells and hTert RPE1
epithelial cell lines following CCT244747 treatment (solid line), or CCT244747 combined with radiation treatment (dashed line). Data normalized to untreated control or
CCT244747 only results and presented as mean ± SEM of at least 3 individual experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. (b) Western blots of lysates from T24,
RT112 and Cal27 cells treated with CCT244747, RT, or a combination of both (CCT244747 and RT) demonstrating drug-on-target effect for each cell line used. Cells were
collected 8 and 12 h after CCT244747 exposure.
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abnormal nuclei
To investigate changes in nuclear and cell morphology follow-
ing RT and CCT244727, cells were stained with c-H2AX and a-
tubulin and analysed by confocal microscopy. Untreated control
cells had mainly normal nuclei (normal size and without micronu-
clei (Fig. S3a and b)) containing few c-H2AX foci (Fig. 2c). Cells
treated with CCT244747 alone had mostly normal nuclear mor-
phology, but there was an increase in the percentage of nuclei con-
taining c-H2AX foci (Fig. S3b) or exhibiting pan–H2AX (Fig. S3b)
staining. As expected, RT increased the number of c-H2AX foci,
and significantly increased the percentage of cells with abnormal
nuclear morphology (Fig. S3b). CCT244747 and RT combination
caused a further increase in the number of cells with abnormal
nuclear morphology, either due to an increase in multinucleation
or the presence of micronuclei (Fig 2c, S3a), suggesting cells were
undergoing mitotic catastrophe. The percentage of cells with c-
H2AX nuclear staining (foci, pan, foci + abnormal, pan + abnormal)
was significantly increased for all cell lines.
To further assess whether cells were undergoing apoptosis, cell
lysates were collected 24 and 48 h after treatment and analysed for
Caspase-3 and PARP cleavage by Western blotting. Single-agent
CCT244747 increased cleaved PARP levels in T24 and Cal 27 at
24 h and in all three cell lines at 48 h. This was accompanied by
an increase in cleaved Caspase-3 levels in T24 and Cal 27 at 48 h.
Radiotherapy increased PARP and Caspase-3 cleavage in T24 and
RT112 but not Cal27 at 48 h. In T24 and Cal27, combination ther-
apy did not result in a further increase in Caspase-3 or PARP cleav-
age (Fig 2d). RT112 cells, showed increased PARP and Caspase-3
cleavage with combination therapy.In vivo radiosensitization by CCT244747
We tested the effect of CCT244747, either alone or in combina-
tion with RT, in Cal27 xenografts in vivo (Fig. 3a). We did not
observe any clinical signs of toxicity (including a less than 5% drop
in body weight) in all 4 treatment groups. The average tumourvolume, which was between 70 and 90 mm3 at day 0, reached
1061 mm3 in the control group after 70 days (Fig. 3b). The increase
in volume was less evident in the drug alone and RT alone groups
compared to the controls (910 vs 879 vs 1061 mm). The mean
tumour volume in the combination therapy group at 70 days was
significantly lower than either drug or radiotherapy alone groups
(445 mm3; P < 0.05 for both). It took 35.4 ± 9.6 days for the
tumours in the combination treatment group to reach a minimum
of 3 times their original volume. In contrast, it took 19.9 ± 3.5 days
in the radiation alone group, 24.7 ± 8.3 days in the CCT244747
alone group and 20 ± 3 days in the control group to reach this size.
The median survival data reflected the lower tumour burden in
the combination group compared with the others (Fig. 3c). Median
survival values increased from 40 days (control and RT alone), to
58 days (drug only) and Not Reached (RT plus CCT244747)
(P < 0.01 vs all other treatment groups). Indeed, the combination
group recorded 75% survival at 70 days, having achieved a stable
average tumour volume of 450 mm3. The combination of RT and
CCT244747 was significantly different from the single treatments
(P = 0.0042) (log–rank Mantel–Cox test).Discussion
Cytotoxic chemotherapy is combined with radiotherapy to treat
muscle invasive bladder cancers and locally advanced HNSCC,
allowing organ preservation [13–15]. Due to the associated side-
effects and poor outcomes, there is a need for less toxic and more
effective treatments. Pre-clinical studies have evaluated several
novel radiosensitizers in bladder cancer models [16–19], but no
agent has translated into clinical trials reporting improved
outcomes.
The current study confirms previously published work regard-
ing the role of Chk1 in mediating tumour radioresistance [20]. This
study demonstrated that the orally active Chk1 inhibitor
CCT244747 radiosensitized tumour cells both in vitro and in vivo,
and the combination demonstrated growth delay in a cancer xeno-
graft model with a survival benefit. Radiosensitization was elicited
Fig. 2. CCT244747 abrogates the RT-induced G2 arrest and drives premature mitotic entry. T24, RT112 and Cal27 were treated with radiation 6 h after administration of
CCT244747. (a) Relative change to various phases of the cell cycle at 12, 24 and 48 h time-points following exposure to CCT244747. DNA content and Mitotic index were
assessed by flow cytometry using propidium iodide and pS10-histone H3. Data are normalized to the untreated ‘control’ samples and presented as mean ± SEM of 3
independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. (b) Western blot showing cell cycle progression markers (pHH3) and DNA damage marker (c-H2AX). (c)
Quantification of immunofluorescent images from cells fixed 24 h after treatment with CCT244747; positive for foci when P5 foci; positive for pan-nuclear staining when
P80% of the nucleus was stained positive for (c-H2AX) and cells with micronuclei and multinucleated cells were considered as abnormal nuclei. (d) Western blot showing
apoptotic markers PARP-1 and caspase-3 at 24 and 48 h.
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Fig. 3. CCT244747 is an in vivo radiosensitizer. Athymic nude mice were injected subcutaneously with 3  106 Cal27 cells and divided in 4 groups. Mice were treated with
CCT244747 (100 mg/kg) by gavage 1 h prior to RT (2 Gy5). (a) Schematic representation of the schedule used to treat the mice. (b) Tumour growth delay (mean ± SD) and (c)
survival.
474 CCT244747 mediated radiosensitizationthrough abrogation of RT-induced G2 cell cycle arrest, forcing cells
into premature mitosis with unrepaired DNA-DSBs. Although pre-
viously described in pre-clinical head and neck cancer models [7],
to our knowledge, this is the first study showing Chk1-mediated
radiosensitization in bladder cancer cells.
Most cancer cells are more dependent than normal cells on the
G2 checkpoint to repair DNA damage, because of a deficient G1
checkpoint [21]. Targeting the G2 checkpoint as an anticancer
strategy has been explored as monotherapy [22] or in combination
with DNA damaging agents [23]. Following DNA damage, Chk1
inhibition prevents G2 arrest forcing cells into premature M phase
and cell death by mitotic catastrophe and/or apoptosis [7].
In addition to cellular signalling, the efficacy of the combination
treatment is dependent on cell cycle perturbation. As demon-
strated previously, Chk1 inhibition was able to overcome RT-
mediated G2 arrest, causing cells to prematurely enter mitosis.
We also observed a decrease in the S phase of the cell cycle 24 h
after RT, which was abrogated in cells treated with CCT244747/
RT combination therapy. Western analysis confirmed these
changes in the cell cycle and also indicated that, despite unrepaired
DNA DSBs remaining at 24 and 48 h after CCT244747/RT therapy,
cells were still entering mitosis (evidenced by the expression of
p-HH3) and, therefore, were likely to undergo mitotic catastrophe.
It has previously been shown that Chk1 inhibition during DNA
replication can lead to disruption of the normal repair and restart
pathways following stalled replication forks [3,12,24]. This can
manifest as pan-nuclear H2AX staining, which has been linked to
replication stress, S phase arrest [25] and apoptosis [12]. Indeed,
our analysis revealed that cells treated with CCT244747/RT combi-
nation therapy exhibited increased pan-nuclear H2AX staining and
abnormal nuclei, which resulted in apoptosis. Cells with pan-
nuclear H2AX staining following RT alone may represent cells with
foci alone, as this population was reduced after the combination of
CCT24474 and RT.
PARP facilitates cellular disassembly and, following cleavage by
Caspase-3, serves as a marker of cells undergoing apoptosis at later
time points. CCT244747 increased cleaved PARP levels at 24 and
48 h, whilst radiotherapy increased cleaved PARP levels at 48 h.
CCT244747 appeared to induce apoptotic cell death 24 h earlierthan radiotherapy. The mode of cell death following irradiation is
dependent on several factors including the cell type and we note
Cal 27 cells did not undergo apoptosis following radiotherapy
alone.
Our in vivo model confirmed the in vitro findings and showed
that CCT244747 radiosensitizes tumour cells. CCT244747 and RT
monotherapies had modest effects on tumour growth, whereas
the combination treatment demonstrated a significant tumour
growth delay that translated into improved survival of the
CCT244747 plus RT group. Based on these data, it will be important
to investigate the combination of CCT244747 and radiation in early
phase clinical trials in an attempt to develop efficacious treatments
with less toxicity than conventional CRT.Conflicts of interest statement
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